Advanced Life Sciences Holdings, Inc.
1440 Davey Road
Woodridge,
IL 60517
United States - Map
Phone: 630-739-6744
Fax: 630-739-6754
Web Site: http://www.advancedlifesciences.com
| Advanced Life Sciences Holdings, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel drugs in the areas of infectious disease, oncology, and respiratory disease. Its lead candidate includes Cethromycin, a novel once-a-day oral antibiotic under review by the FDA for the treatment of mild-to-moderate community acquired pneumonia. Cethromycin has also completed Phase III clinical trials for the treatment of respiratory tract infections. The company also has an exclusive worldwide license agreement with Abbott Laboratories for the development and commercialization of Cethromycin. Advanced Life Sciences products under preclinical studies comprise ALS-357, a compound for the treatment of malignant melanoma; and ALS-886, a novel therapeutic for the treatment of inflammation-related tissue damage consisting of tissue damage associated with acute respiratory distress syndrome. Its products under preclinical studies also include product candidates derived from the companys natural products-based chemistry platform. Advanced Life Sciences has collaborations and license agreements with Wyeth Pharmaceuticals, University of Illinois at Chicago, Baxter International, National Institute of Allergy and Infectious Diseases, and Defence Science and Technology Laboratory of the United Kingdom. The company was founded in 1999 and is headquartered in Woodridge, Illinois. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Michael T. Flavin Ph.D., 51
Founder, Chairman and Chief Exec. Officer |
N/A
| N/A | Mr. John L. Flavin , 38
Pres, Chief Financial Officer, Sec. |
N/A
| N/A | Dr. Ze-Qi Xu Ph.D., 47
Chief Scientific Officer, Exec. VP and Sec. of Advanced Life Sciences Inc |
N/A
| N/A | Dr. David A. Eiznhamer Ph.D., 45
Exec. VP of Clinical Devel. |
N/A
| N/A | Mr. Mark Caputo , 44
Chief Accounting Officer of Accounting |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.49% Nasdaq 
0.001 (0.57%) 
Profile
